AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo

被引:49
作者
Perry, Betsy
Banyard, Jacqueline
McLaughlin, Elizabeth R.
Watnick, Randy
Sohn, Allie
Brindley, David N.
Obata, Toshiyuki
Cantley, Lewis C.
Cohen, Cynthia
Arbiser, Jack L.
机构
[1] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA
[2] Childrens Hosp Boston, Dept Surg, Vasc Biol Program, Boston, MA USA
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Signal Transduct, Boston, MA 02215 USA
[4] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[5] MIT, Cambridge, MA 02139 USA
[6] Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB, Canada
关键词
D O I
10.1001/archderm.143.4.504
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Vascular malformations are clinical disorders in which endothelial cells fail to remodel and/or undergo programmed cell death, leading to abnormal persistence of blood vessels. The abnormal persistence of vessels makes therapy difficult because these lesions are resistant to interventions that are effective against hemangiomas. Akt1 is a serine-threonine protein kinase, which is a key mediator of resistance to programmed cell death. Our objective was to determine whether sustained activation of Akt1 could lead to vascular malformation in mice. Observations: We examined the effect of constitutive activation of Akt1 in murine endothelial cells (MS1 cells). Overexpression of active AKT1 in MS1 cells led to the development of vascular malformations, characterized by wide endothelial lumens and minimal investment of smooth muscle surrounding the vessels. The histologic features of these vascular malformations is distinct from ras-transformed MS1 cells (angiosarcoma) and suggest that differing signal abnormalities give rise to human vascular malformations vs malignant vascular tumors. Conclusions: Inhibition of Akt signaling may be useful in the treatment of vascular malformations. Examination of problematic hemangiomas and vascular malformations for the presence of activated Akt or downstream targets of Akt, such as mammalian target of rapamycin (mTOR), may predict response to treatment with Akt inhibitors or rapamycin. This study provides a potential rationale for the systemic and topical use of these inhibitors for vascular malformations and hemangiomas.
引用
收藏
页码:504 / 506
页数:3
相关论文
共 16 条
[1]   Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways [J].
Arbiser, JL ;
Moses, MA ;
Fernandez, CA ;
Ghiso, N ;
Cao, YH ;
Klauber, N ;
Frank, D ;
Brownlee, M ;
Flynn, E ;
Parangi, S ;
Byers, HR ;
Folkman, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :861-866
[2]   Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy [J].
Belay, AD ;
Asafa, Y ;
Mesure, J ;
Davidson, RN .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2006, 100 (03) :223-227
[3]   A RETROVIRAL ONCOGENE, AKT, ENCODING A SERINE-THREONINE KINASE CONTAINING AN SH2-LIKE REGION [J].
BELLACOSA, A ;
TESTA, JR ;
STAAL, SP ;
TSICHLIS, PN .
SCIENCE, 1991, 254 (5029) :274-277
[4]  
Chiller Katarina G, 2003, Lymphat Res Biol, V1, P267, DOI 10.1089/153968503322758076
[5]   Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma [J].
El-Hashemite, N ;
Zhang, HB ;
Henske, EP ;
Kwiatkowski, DJ .
LANCET, 2003, 361 (9366) :1348-1349
[6]  
FROMENT O, 1994, CANCER RES, V54, P5340
[7]   P53 MUTATIONS AT A-T BASE-PAIRS IN ANGIOSARCOMAS OF VINYL CHLORIDE-EXPOSED FACTORY-WORKERS [J].
HOLLSTEIN, M ;
MARION, MJ ;
LEHMAN, T ;
WELSH, J ;
HARRIS, CC ;
MARTELPLANCHE, G ;
KUSTERS, I ;
MONTESANO, R .
CARCINOGENESIS, 1994, 15 (01) :1-3
[8]   Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells [J].
LaMontagne, KR ;
Moses, MA ;
Wiederschain, D ;
Mahajan, S ;
Holden, J ;
Ghazizadeh, H ;
Frank, DA ;
Arbiser, JL .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (06) :1937-1945
[9]   Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis [J].
Nadiminti, U ;
Arbiser, JL .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) :S17-S19
[10]   Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway [J].
Papapetropoulos, A ;
Fulton, D ;
Mahboubi, K ;
Kalb, RG ;
O'Connor, DS ;
Li, FZ ;
Altieri, DC ;
Sessa, WC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (13) :9102-9105